This Article Full Text Full Text (PDF) Data Supplement Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morton, R. F. Articles by Hammond, E. H. Search for Related Content PubMed Articles by Morton, R. F. Articles by Hammond, E. H. Social Bookmarking                            What's this?

ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab—Clinical Implications in Colorectal Cancer

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

The impetus for ASCO's provisional clinical opinion (PCO) is to alert oncologists of emerging information from recent clinical trials that will assist them in treatment selection of monoclonal antibody therapy for their patients with metastatic colorectal cancer. Accumulating evidence strongly suggests that cetuximab and panitumumab are ineffective in patients with KRAS mutations at codon 12 or 13. Thus, colorectal cancer patients with these mutations should be spared the toxicity and economic cost of an ineffective therapy. Presently, it is unknown whether there are other KRAS mutations that render anti-EGFR agents ineffective.

The ASCO Health Services Committee (HSC) is charged with . . . [Click for More]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. V. Cox Medicare's Seasons J. Oncol. Pract, March 1, 2009; 5(2): 49 - 49. [Full Text] [PDF]

				C. Stokoe Adapting Practice in the Face of New Data J. Oncol. Pract, March 1, 2009; 5(2): 83 - 85. [Full Text] [PDF]